Skip to main content
. Author manuscript; available in PMC: 2022 Jul 27.
Published in final edited form as: Cell Rep. 2022 Jun 7;39(10):110930. doi: 10.1016/j.celrep.2022.110930

Figure 2. Baseline serostatus impacts genotype cross-neutralization.

Figure 2.

DENV4 GI and II neutralization titers by A) seronegative and B) seropositive post-vaccination immune sera. FRNT50 represents sera dilution factor required to neutralize 50% of virus. Dotted line represents limit of detection (20). Samples not neutralized are graphed at ½ the limit of detection (10). Neutralization titers against GI and GII viruses were compared by unpaired t-test (***p<0.001).